Treatment · Essay 04

ADHD medication best practices: what optimized treatment looks like

The most important ADHD medication study ever run didn't discover a better drug. It proved that a better method — with the same drugs — produced better children's lives.

Reviewed by Edward Ratush, MD · July 2026 · Citations: evidence ledger

The MTA lesson

In the multi-site MTA trial, children randomized to protocol-driven medication management — careful initial titration, monthly monitoring, teacher input feeding every dose decision — did significantly better on core symptoms than children receiving routine community care, most of whom were taking the same class of medication. Method beat molecule. That finding is the founding argument of this practice, and it should change what you accept as normal care.

The toolbox, honestly described

• Stimulants (methylphenidate and amphetamine classes) are first-line for good reason: large, well-replicated effects, decades of safety data under proper supervision, and — in the largest network meta-analysis — methylphenidate carrying the best efficacy-tolerability balance for children. Formulation matters as much as milligrams: release curves determine whether coverage matches a school day.
• Non-stimulants — atomoxetine, viloxazine, guanfacine, clonidine — are slower and typically less potent on core symptoms, but essential when stimulants aren't tolerated, when appetite, sleep, tics, or anxiety complicate the picture, or as evening-coverage partners alongside a stimulant.

Titration done properly

Start low. Change one variable at a time. Define the observation window and the measures before the change — repeated scales, school input, targeted questions about the hours that matter — then judge against them. The right dose is the lowest one that delivers verified benefit, not the highest one without complaints. And a dose that was right at eight is not automatically right at eleven: growth, puberty, and rising school demands all move the target.

Side effects: managed, not endured

Appetite suppression and its effect on growth (measurable in long-term follow-up data, and manageable with dose timing, formulation, and calorie strategy), sleep disruption, evening irritability or "rebound," mood changes, tics, heart rate and blood pressure — each has a monitoring plan and a management playbook. A family quietly tolerating any of these for months is the signature of unmanaged treatment.

Signs your child's treatment is on autopilot

• The dose hasn't been re-examined in over a year despite growth or new school demands
• No one has collected a teacher rating since the diagnosis
• "How's it going?" is the entire monitoring protocol
• Afternoons and homework are chaos, and no one has mapped coverage timing
• Side effects get sympathy but no plan